Aeterna Zentaris Inc
-0.09 (-2.42%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 6,711
Bid Price 3.13
Ask Price 4.00
News -
Day High 3.8711


52 Week Range


Day Low 3.72
Company Name Stock Ticker Symbol Market Type
Aeterna Zentaris Inc AEZS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.09 -2.42% 3.63 20:00:00
Open Price Low Price High Price Close Price Prev Close
3.74 3.72 3.8711 3.82 3.72
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
82 6,711 $ 3.84 $ 25,752 - 0.1645 - 5.90
Last Trade Time Type Quantity Stock Price Currency
17:14:45 formt 100 $ 3.63 USD


Draw Mode:

Aeterna Zentaris Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 17.63M 4.86M 4.85M $ 5.26M $ - -1.87 -1.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Aeterna Zentaris News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AEZS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.663.943.663.7811,766-0.03-0.82%
1 Month3.383.943.373.7613,2790.257.4%
3 Months3.684.002.893.5715,776-0.05-1.36%
6 Months4.635.902.894.5130,626-1.00-21.6%
1 Year0.355.900.16450.4433629431,9413.28937.14%
3 Years1.035.900.16451.133,029,2632.60252.43%
5 Years2.055.900.16451.201,920,6841.5877.07%

Aeterna Zentaris Description

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.